Valproic acid-expanded cord blood CD34+CD90+ cells are functionally distinct based on their origin
Stem Cells · 2025
DOI: 10.1093/stmcls/sxaf079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells, 2025. Verfasst von Al Rabee Kassis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of Illinois College of Medicine, Chicago, IL 60612, United States. Hauptthemen laut MEDLINE: Valproic Acid, Fetal Blood, Antigens, CD34, Hematopoietic Stem Cells. Gefördert von: Michael Reese Pioneer in Research.
Abstract (Originalsprache)
Hematopoietic stem cell (HSC) transplantation is a potentially curative option for patients with hematologic malignancies, but donor shortages impact graft availability. Umbilical cord blood (UCB) is a viable alternative source of HSC, however the limited numbers present in a single unit have spurred efforts to expand HSC ex vivo. We previously demonstrated that the addition of valproic acid (VPA), an anti-convulsive drug, to CB cell cultures promotes maintenance of functional HSC, but not expansion. However, it has been proposed that VPA primarily induces mitochondrial reprogramming of mature CD34+CD90– cells to more primitive CD34+CD90+ cells, rather than the replication of CD34+CD90+ cells in culture. To determine which fraction of the CD34+CD90+ cells present after culture in VPA were derived from CD34+CD90– vs. CD34+CD90+ cells, we examined the functionality of CD34+CD90+ cells derived from each flow cytometry-sorted population. During culture in VPA there was a significant increase in CD34+CD90+ cell number; the majority arising from pre-existing CD34+CD90+ cells, with minimal contribution from CD34+CD90– cells. Colony-forming unit (CFU) assays revealed reduced plating efficiency and xeno-transplantation studies demonstrated diminished in vivo hematopoietic reconstitution potential of CD34+CD90+ cells derived from relatively committed CD34+CD90– cells. Our findings indicate that while VPA supports CD34+CD90+ cell expansion, the CD34+CD90+ cells derived from CD34+CD90– cells are functionally more differentiated than those derived directly from CD34+CD90+ cells, with increased mitochondrial mass and membrane potential, but reduced regenerative potential. These results emphasize the need for functional assessments of culture-expanded HSCs to accurately determine their therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, University of Illinois College of Medicine, Chicago, IL 60612, United States.
- Clinical Stem Cell Laboratory, UI Blood & Marrow Transplant Program, UI Health, Chicago, IL 60612, United States.
- University of Illinois Cancer Center, Chicago, IL 60612, United States.
ORCID-Profile: Nadim Mahmud
Förderung
- Michael Reese Pioneer in Research
Zitieren
APA
Kassis, A. R., Ganapathy, A., Mechaal, A., An, S., Quigley, J. G., Mahmud, D., & Mahmud, N. (2025). Valproic acid-expanded cord blood CD34+CD90+ cells are functionally distinct based on their origin. Stem Cells. https://doi.org/10.1093/stmcls/sxaf079
Vancouver
Kassis AR, Ganapathy A, Mechaal A, An S, Quigley JG, Mahmud D, et al. Valproic acid-expanded cord blood CD34+CD90+ cells are functionally distinct based on their origin. Stem Cells. 2025. doi:10.1093/stmcls/sxaf079
BibTeX
@article{Kassis2025,
author = {Kassis, Al Rabee and Ganapathy, Amudha and Mechaal, Amal and An, Seungwon and Quigley, John G and Mahmud, Dolores and Mahmud, Nadim},
title = {Valproic acid-expanded cord blood CD34+CD90+ cells are functionally distinct based on their origin},
journal = {Stem Cells},
year = {2025},
doi = {10.1093/stmcls/sxaf079}
}
EUVIMED